Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzyme Engineering . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113755462B reveals high-activity enzyme mutants for chiral beta-amino acid synthesis, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN117247928A details mutant acylase for 7-ACA. Offers greener, efficient production for reliable pharmaceutical intermediates supplier partners.
Patent CN104531630B enables high-enantioselectivity enzyme mutants. Achieve substantial cost reduction in pharma intermediates manufacturing with scalable biocatalysis.
Patent CN112063610B details TPL mutants achieving 146g/L L-DOPA. Offers superior catalytic efficiency for pharmaceutical manufacturing supply chains.
Patent CN106795542B details (R)-selective cupin enzymes for chiral beta-nitroalcohol synthesis, offering high purity and cost reduction in API manufacturing.
Patent CN119698468A details engineered transaminases for niraparib synthesis, offering high stereoselectivity and scalable biocatalytic solutions for pharmaceutical supply chains.
Patent CN111172124B details a YOL151W mutant for high-concentration synthesis, offering cost-effective pharma intermediate manufacturing.
Novel dual-enzyme mutant catalyst enhances (S)-Bosone production efficiency. Reduces cofactor costs and improves supply chain reliability for cosmetic manufacturers.
Patent CN116948997B reveals high-purity enzymatic route for Brivaracetam intermediate. Offers significant cost reduction and supply chain reliability for global pharmaceutical manufacturing.
Patent CN120290522A reveals high-efficiency pyridoxal kinase mutants for vitamin manufacturing. Achieve lower costs and scalable supply chain reliability today.
Patent CN106995807B reveals high-activity transaminase for Sitagliptin. Enables cost reduction in pharmaceutical intermediates manufacturing with superior enantioselectivity.
Novel engineered ketoreductase enables high optical purity synthesis of chiral intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Novel enzyme mutant enables high-purity drug intermediate synthesis with improved conversion rates and industrial scalability for global supply chains.
Patent CN116024284A reveals mutant imine reductase for S-nicotine. Achieve >99% ee and high conversion. Reliable pharmaceutical intermediate supplier for cost reduction.
Novel acetamidase mutant enables high-purity chiral acid production. Reduces costs and improves supply chain reliability for pharmaceutical intermediate manufacturing globally.
Patent CN119823959B reveals novel imine reductase mutants for high-purity chiral amine synthesis, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN112852894A reveals SpAmDH mutant for high-purity chiral amino alcohol. Enables cost reduction and scalable supply chain for pharmaceutical intermediates.
Patent CN110904086A reveals a novel tryptophanase mutant for D-tryptophan production. Discover cost-effective biocatalytic solutions and reliable supply chain strategies.
Patent CN103937759B reveals a novel biocatalytic route for statin intermediates. Discover cost reduction and supply chain reliability advantages for pharmaceutical manufacturing.
Patent CN115772508B reveals high-activity DAAO mutants for efficient L-glufosinate intermediate production, offering significant cost and supply chain advantages.